<DOC>
	<DOCNO>NCT02796339</DOCNO>
	<brief_summary>The purpose study assess effectiveness supplement natural Mastiha Inflammatory Bowel Diseases ( IBD ) . U.S. Food Drug Administration classify Mastiha GRAS . Previous research demonstrate Mastiha 's safety , well anti-inflammatory , antimicrobial antioxidant property . In addition , European Medicine Agency recently recognize Mastiha natural medicine classify category traditional herbal medicine diarrhea problem , mild dyspeptic disorder , skin inflammation healing ( EMA/HMPC/46758/2015 ) . Since IBD chronic disease characterize inflammation oxidative stress base previous small-scale study , present study aim demonstrate effectiveness supplement adjunct conservative treatment IBD . To end , confirm IBD patient , distinguish Ulcerative Colitis ( UC ) Crohn 's Disease ( CD ) enrol base certain inclusion exclusion criterion . The staff study provide detail information regard aim , method , anticipate benefit potential hazard study patient receive Patient Information Leaflet ( PIL ) . Ample time ( 48 hour ) provide order decide whether want participate protocol . Each patient agree participate sign Informed Consent document staff explain patient obligation enter trial withdraw time trial , without give reason . A copy sign Informed Consent give participant . 100 IBD patient allocate either Mastiha placebo group . The Mastiha group receive natural Mastiha supplement dose 2.8 g daily placebo group receive respectively placebo . The intervention last 3 month patient relapse 6 month patient remission . They receive supplement consume intervention start trial . Both group continue medical treatment , must unaltered throughout trial . Additionally , patient receive standard nutritional advice dietician encourage report adverse effect may experience intervention . The trial blind implicated person ; neither staff trial patient aware kind intervention receive . Patients assess randomisation accord following tool : - Medical history - Dietary history - Harvey &amp; Bradshaw Activity Index Assessment - Mayo Activity Index assessment - Anthropometric data measurement : body weight ( kg ) , height ( cm ) , Body Mass Index ( kg/m2 ) - Inflammatory Bowel Disease Questionnaire - DNA isolation whole blood . - Biochemical measurement : Complete blood count , albumin , lipid profile , glucose , electrolytes , liver enzymes , amylase , fibrinogen . - Evaluation inflammation serum sample . Circulating serum level IL-6 , IL-8 , IL-17A , IL-17F , IL-18 , IL-21 , IL-22 , TL1A , TGF-β , ICAM-1 , MADCAM-1 E-selectin measure ) , active CD UC patient . Inflammatory marker also estimate stool sample : calprotectin , lactoferrin lysozyme , - Oxidative stress assessment serum/plasma sample . Oxidised LDL , serum oxidisability F2-isoprostanes quantify . - Detection metabolites complete metabolomic profile plasma sample . - Stool sample collection assessment gut microbiota active patient . - Genetic epigenetic profile Subsequent assessment : There biweekly telephone contact patient monitor compliance side effect . At end intervention subject undergoes baseline assessment .</brief_summary>
	<brief_title>A Study Effectiveness Nutritional Supplement With Natural Mastiha Inflammatory Bowel Diseases .</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Eligibility criterion patient relapse Inclusion criterion : Age 1867 year Active disease , CD define Harvey &amp; Bradshaw Activity Index ≥4 ; UC define Partial Mayo Clinic Score ( 2 &lt; = Mayo Scoring Index ) Childbearing age negative pregnancy test eligibility baseline assessment Stable treatment steroid least 2 week start trial , mesalamine mesalamine analogue 4 week immunosuppressants 8 week Stable medication whole period 3month intervention Exclusion criterion : Positive stool culture enteric pathogen Clostridium difficile toxin Antibiotic treatment 2 month prior screen Bowel surgery ≤3 month prior screen ; plan elective surgery hospitalisation study ; clinically significant short bowel syndrome ; presence intraabdominal abscess fistula clinical radiological evidence associate abscess ; ileostomy ; colostomy Enteral parenteral nutrition ; Alcohol drug abuse , Vitamin inorganic supplement , vegan macrobiotic diet trial Any malignancy year prior screening ; CVD ; peptic ulcer Pregnancy , lactation Eligibility criterion patient remission Inclusion criterion : Age 1867 year Inactive disease ( &gt; 3 month ) , CD define Harvey &amp; Bradshaw ( &lt; 6 Index ) UC define Partial Mayo Clinic ( 01 Mayo Scoring Index ) Biochemical remission Childbearing age negative pregnancy test eligibility baseline assessment Stable treatment azathioprine mesalamine mesalamine analogue Stable medication whole period 6month intervention Exclusion criterion : Positive stool culture enteric pathogen Clostridium difficile toxin Antibiotic treatment 2 month prior screen Bowel surgery ≤3 month prior screen ; plan elective surgery hospitalisation study ; clinically significant short bowel syndrome ; presence intraabdominal abscess fistula clinical radiological evidence associate abscess ; ileostomy ; colostomy Enteral parenteral nutrition ; Alcohol drug abuse Vitamin inorganic supplement , vegan macrobiotic diet trial Any malignancy year prior screening ; CVD ; peptic ulcer Pregnancy , lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>67 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Inflammatory Bowel Diseases</keyword>
	<keyword>natural Mastiha</keyword>
	<keyword>supplement</keyword>
</DOC>